Results 331 to 340 of about 8,503,937 (347)
Some of the next articles are maybe not open access.
Annales d'Endocrinologie, 2021
FGF23 is a protein secreted in the plasma by bone cells. In the kidney, FGF23 can activate an FGF receptor in the presence of its co-receptor αKlotho. FGF23 controls the renal phosphate reabsorption and calcitriol metabolism. When renal function declines, plasma FGF23 concentration raises and FGF23 can stimulate FGFRs in the absence of αKlotho.
openaire +3 more sources
FGF23 is a protein secreted in the plasma by bone cells. In the kidney, FGF23 can activate an FGF receptor in the presence of its co-receptor αKlotho. FGF23 controls the renal phosphate reabsorption and calcitriol metabolism. When renal function declines, plasma FGF23 concentration raises and FGF23 can stimulate FGFRs in the absence of αKlotho.
openaire +3 more sources
Cardiovascular Risk Assessment
Medical Clinics of North America, 2017Cardiovascular risk assessment is fundamental to prevention of cardiovascular disease, because it helps determine the size of the potential benefits that might accrue to individual patients from use of statins, aspirin, and other preventive interventions.
Andrew E. Moran, Mark J. Pletcher
openaire +3 more sources
Erythropoietin and Cardiovascular Risk
Blood Purification, 1995We studied the changes in some cardiovascular risk (CVR) factors in 24 maintenance hemodialysis patients treated for 1 year with recombinant human erythropoietin (rHuEPO) either intravenously (12 cases) or subcutaneously (12 cases). In order to clarify whether changes in some parameters were due to direct action of rHuEPO or to changes in food intake ...
A. Vasile +3 more
openaire +3 more sources
Estrogens and Cardiovascular Risk
JAMA: The Journal of the American Medical Association, 1988To the Editor. —We were surprised to see our recent study 1 badly misrepresented in the title and lead-in of the MEDICAL NEWS & PERSPECTIVES story entitled "Will Epidemiology Answer the Estrogen Question?" 2 The story appeared to suggest that this study questioned the cardiovascular protection from postmenopausal estrogen therapy.
Graham A. Colditz, Meir J. Stampfer
openaire +2 more sources
Obesity and cardiovascular risk
Growth Hormone & IGF Research, 2003In most industrialized countries, 40-60% of the population is now overweight or obese. Obesity has recently been recognized as a major modifiable risk factor for cardiovascular disease, second only to cigarette smoking. Excess weight and obesity markedly increase the risk for hypertension, diabetes, coronary artery disease and congestive heart failure ...
openaire +3 more sources
Cardiovascular Risks with Azithromycin
New England Journal of Medicine, 2013Henrik, Svanström +2 more
openaire +8 more sources
Celecoxib and cardiovascular risks
Expert Opinion on Drug Safety, 2005In a very short time, COX-2 enzyme inhibitors have gone from the darlings to the pariahs of the pharmaceutical industry. These drugs were developed based on the hypothesis whereby selective inhibition of the COX enzyme would lead to reduction in pain and inflammation without associated gastrointestinal and bleeding risks.
openaire +3 more sources
The American Journal of Cardiology, 2001
Cardiovascular disease mortality rates have decreased in men during the past 20 years, but have steadily increased in women. In the United States, >500,000 women die of coronary artery disease (CAD) every year. Although many factors can influence an individual's risk for CAD, some factors are unique to women, including reproductive status. Menopause is
openaire +3 more sources
Cardiovascular disease mortality rates have decreased in men during the past 20 years, but have steadily increased in women. In the United States, >500,000 women die of coronary artery disease (CAD) every year. Although many factors can influence an individual's risk for CAD, some factors are unique to women, including reproductive status. Menopause is
openaire +3 more sources